Goldman Sachs
RKDA icon

Goldman Sachs’s Arcadia Biosciences RKDA Stock Holding History

Goldman Sachs’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-276
Closed -$2.99K – 6178
2022
Q4 		$2.99K Buy
+276
New +$3.93K ﹤0.01% 5848
2021
Q3 		– Sell
-792
Closed -$94K – 6466
2021
Q2 		$94K Buy
+792
New +$86.3K ﹤0.01% 5961
2018
Q1 		– Sell
-26
Closed -$6K – 6313
2017
Q4 		$6K Buy
+26
New +$5.63K ﹤0.01% 6239
2017
Q3 		– Sell
-16
Closed -$6K – 6824
2017
Q2 		$6K Hold
16
– – ﹤0.01% 6684
2017
Q1 		$9K Sell
16
-4
-20% -$2.87K ﹤0.01% 6621
2016
Q4 		$15K Sell
20
-9
-31% -$10.2K ﹤0.01% 6706
2016
Q3 		$44K Buy
29
+16
+123% +$28.3K ﹤0.01% 6519
2016
Q2 		$28K Sell
13
-6
-32% -$10K ﹤0.01% 6611
2016
Q1 		$42K Buy
19
+4
+27% +$8.5K ﹤0.01% 6505
2015
Q4 		$36K Sell
15
-88
-85% -$229K ﹤0.01% 6685
2015
Q3 		$252K Buy
+103
New +$429K ﹤0.01% 5773

Other funds holding RKDA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's RKDA Position: Q1 2023 in Review

Goldman Sachs sold out of Arcadia Biosciences (RKDA) in Q1 2023, closing a stake of 276 shares — an estimated $2.99K sold.

Goldman Sachs first reported a position in RKDA in Q3 2015 and held it in 11 quarters. The position peaked at $252K in Q3 2015. 15 funds tracked by Wall St. Rank hold RKDA as of Q1 2023.

  • Goldman Sachs reported no remaining Arcadia Biosciences position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 276 Arcadia Biosciences shares in Q1 2023, an estimated $2.99K.
  • Goldman Sachs first reported a position in Arcadia Biosciences in Q3 2015 and held it in 11 quarters.
  • Goldman Sachs's Arcadia Biosciences position peaked at $252K in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.